Glycosylation alterations in lung and brain cancer.
Alterations in glycosylation are common in cancer and are thought to contribute to disease. Lung cancer and primary malignant brain cancer, most commonly glioblastoma, are genetically heterogeneous diseases with extremely poor prognoses. In this review, we summarize the data demonstrating that glycosylation is altered in lung and brain cancer. We then use specific examples to highlight the diverse roles of glycosylation in these two deadly diseases and illustrate shared mechanisms of oncogenesis. In addition to alterations in glycoconjugate biosynthesis, we also discuss mechanisms of postsynthetic glycan modification in cancer. We suggest that alterations in glycosylation in lung and brain cancer provide novel tumor biomarkers and therapeutic targets.
Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, California, USA.
Hassan
H
Lemjabbar-Alaoui
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA.
Andrew
A
McKinney
Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, California, USA.
Yi-Wei
YW
Yang
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA.
Vy M
VM
Tran
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA; Department of Pathology, University of California, San Francisco, California, USA. Electronic address: Joanna.Phillips@ucsf.edu.
Joanna J
JJ
Phillips
D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology*; D006023:Glycoproteins / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology*; D009363:Neoplasm Proteins / Q000378:metabolism*
D006023:Glycoproteins; D009363:Neoplasm Proteins
Biomarker; GBM; Glioblastoma; Glycosylation in cancer; HPSE; HSPG; Lung cancer; SULF